| Name | Lidoflazine |
|---|---|
| Synonyms |
R-7904
6’-xylidide,4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2 lidoflazinum lidoflazin 4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2’,6’-xylidide 1-piperazineacetamide,4-(4,4-bis(4-fluorophenyl)butyl)-n-(2,6-dimethylphenyl Lidoflazine Solution, 1000ppm Lidoflazine >= (HPLC), powder ordiflazine Lidoflazine Solution, 100ppm corflazine mcn-jr7904 LIDOFLAZINE, //BP 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide 4-[4,4-Bis(4-fluorophenyl)butyl]-N-(2,6-dimethylphenyl)-1-piperazineacetamide LIDOFLAZINE 1-(4,4-bis(4-fluorofenil)butil)-4-((2,6-dimetilanilinocbonil)metil)piperaz klinium lidoflazina clinium |
| Description | Lidoflazine is a high affinity blocker of the HERG (human ether-a-go-go-related gene) K+ channel. Lidoflazine is an antianginal calcium channel blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia[1]. |
|---|---|
| Target |
Ca2+ |
| In Vitro | Lidoflazine inhibits potently HERG current (IHERG) recorded from HEK 293 cells stably expressing wild-type HERG (IC50 of ~16 nM). |
| References |
| Density | 1.161g/cm3 |
|---|---|
| Boiling Point | 632.6ºC at 760mmHg |
| Melting Point | 158-162ºC |
| Molecular Formula | C30H35F2N3O |
| Molecular Weight | 491.61500 |
| Flash Point | 336.4ºC |
| Exact Mass | 491.27500 |
| PSA | 35.58000 |
| LogP | 5.69880 |
| Appearance | white |
| Index of Refraction | 1.581 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: ≥10mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
|---|---|
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R22 |
| Safety Phrases | 36 |
| RIDADR | NONH for all modes of transport |
| RTECS | TK7910000 |